{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.89","value":"23"},{"groupId":"OG001","spread":"20.18","value":"23.7"}]}],"title":"Disease Effects Scale: Baseline (n=209, 102)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.12","value":"15.0"},{"groupId":"OG001","spread":"14.16","value":"15.9"}]}],"title":"Disease Effects Scale: Cy4D1 (n=176, 86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.83","value":"31.2"},{"groupId":"OG001","spread":"24.65","value":"27.6"}]}],"title":"Fatigue Scale: Baseline (n=209, 102)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.51","value":"20.9"},{"groupId":"OG001","spread":"22.20","value":"23.4"}]}],"title":"Fatigue Scale: Cy4D1 (n=176, 86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.14","value":"47.7"},{"groupId":"OG001","spread":"33.53","value":"50.8"}]}],"title":"Future Health: Baseline (n=206, 101)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.74","value":"29.5"},{"groupId":"OG001","spread":"30.33","value":"39.1"}]}],"title":"Future Health: Cy4D1 (n=175, 86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.91","value":"12"},{"groupId":"OG001","spread":"17.97","value":"14.6"}]}],"title":"Infection Scale: Baseline (n=209, 102)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.65","value":"8.9"},{"groupId":"OG001","spread":"10.70","value":"8.5"}]}],"title":"Infection Scale: Cy4D1 (n=176, 86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.99","value":"24.3"},{"groupId":"OG001","spread":"33.26","value":"26.3"}]}],"title":"Social Problems: Baseline (n=206, 100)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.75","value":"19.4"},{"groupId":"OG001","spread":"27.00","value":"22.0"}]}],"title":"Social Problems: Cy4D1 (n=175, 85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.7","value":"19.8"},{"groupId":"OG001","spread":"15.27","value":"17.2"}]}],"title":"Treatment Side Effects Scale: Baseline (n=209,102)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.68","value":"14.7"},{"groupId":"OG001","spread":"16.11","value":"15.6"}]}],"title":"Treatment Side Effect Scale: Cy4D1(n=176,86)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"description":"EORTC Quality of Life Questionnaire (QLQ-CLL16) module was used to assess patient-reported outcomes and symptom burden. The QLQ-CLL16 module includes three multi-item scales assessing fatigue (2 items), treatment side effects and disease symptoms (8 items), infection (4 items) and two single item scales on social activities and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[First infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"OG000","title":"Obinutuzumab + Chlorambucil (GClb)"},{"description":"Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.","id":"OG001","title":"Chlorambucil (Clb)"}],"paramType":"MEAN","populationDescription":"ITT population. Here, n signifies the number of participants who were evaluated for specified categories.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 4 Day 1 (Cy4D1)","title":"European Organization for Research and Treatment of Cancer (EORTC) QLQ-CLL16 Questionnaire Score","type":"SECONDARY","unitOfMeasure":"unit on a scale"}